Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)

Study Overview

This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).

Study Description

An open-label proof of concept study regarding the use of Secukinumab (Cosentyx) in patients with necrobiosis lipoidica diabeticorum (NLD)

  • Identifier: NCT03791060
  • Protocol Number: 2018P000634
  • Principal Investigator: Alexandra Kimball
  • Principal Investigator: Martina Porter

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000